In this episode, hosts Anthony Davies and Michael Adeniya get to talk to two cell therapy CMC experts in Delfi Krishna, Director Cell and Gene Therapy Platform: R&D Strategy at GSK and Jacob Peterson, Corporate Vice President Head of Stem Cell R&D with Novo Nordisk.
The discussion tackled cellular analytics, manufacturing and the impact the Covid-19 pandemic is having on both capacity and clinical pipelines. Delfi kicks us off with her company’s challenge around managing the cost of goods for autologous therapies…
A special thanks to Jacob for joining us from vacation!
And here’s the link to the European CDMO map mentioned in the video.